Histological Activity and Cirrhosis in Patients with Chronic Hepatitis B

Kris R. Jatana^*
*Correspondence: Kris R. Jatana, Department of Otolaryngology-Head and Neck Surgery, The Ohio State University, Columbus, OH 43212, USA, Email:

Introduction

Around 350 million people are thought to be infected with the hepatitis B virus (HBV), which is still a problem for global public health. The dynamic process of HBV infection, whose prevalence is rising, is influenced by both the individual's immune response and HBV replication. Based on the levels of blood hepatitis B envelope antigen (HBeAg), hepatitis B virus DNA, alanine aminotransferase (ALT), and liver inflammation, the disease is categorised into many phases. The effects of HBV infection can last a lifetime because the illness can progress to cirrhosis, liver failure, and hepatocellular cancer and become chronic (HCC). Every year, about a million people die from cirrhosis and/or HCC as a result of HBV.

To determine the biochemical parameters that were connected to the histopathological alterations seen in patients with high levels of HBV DNA HBeAg positivity, univariate and multivariate analyses of the clinical parameters and histological abnormalities in liver tissues were performed. Through the analysis of liver biopsy results, this study not only helped us better understand the course of chronic HBV diseases and build future prevention and treatment strategies, but it also assisted in identifying the clinical risk factors for the need for therapy. Ultrasonography was used to guide percutaneous liver biopsy in all individuals. 16-G tru-cut biopsy needles were used to perform a liver biopsy (Menghini, Bard Company of America). For a proper diagnosis, there had to be at least 4 portal tracts and 1.5 cm of liver tissue [1].

Description

The Shenzhen Traditional Chinese Medicine Hospital's Department of Pathology received the samples and immediately fixed them, paraffinembedded them, stained them with haematoxylin-eosin, and delivered them there. Two seasoned pathologists blinded to the individuals' clinical data graded the samples obtained using the Knodell histological activity index (HAI) and the Ishak's system.The prevalence of chronic liver disease (CLD) around the globe necessitates the improvement of diagnostic and prognostic tools for the early and precise diagnosis and management of disease. No of the cause, a liver biopsy enables direct microscopic visualisation of the specimen. It simplifies the histological assessment of morphological changes caused by particular diseases. As a result, it helps with disease diagnosis, prognosis, and evaluation of therapy adherence and response. Although liver biopsy is now used less frequently than in the past due to the development of non-invasive techniques, it is still the gold standard for staging and grading a number of CLDs. This quick review goes through liver biopsy again. It emphasises the value of liver biopsies in the assessment of CLDs and describes the widely used Ishak, METAVIR, and Batts-Ludwig scoring systems for classifying and staging CLDs [2].

Chronic liver disease (CLD) encompasses diseases caused by a variety of etiologies, including viral (B and C) and alcoholic hepatitis, nonalcoholic steatohepatitis, haemochromatosis, autoimmune illness, Wilson's disease, and alpha-1 antitrypsin deficiency. Regardless of the aetiology, CLD pathophysiology typically consists of a series of overlapping stages with no obvious boundaries. Hepatic steatosis (fatty liver) is usually followed by steatohepatitis (fatty liver and concurrent inflammation) or hepatitis (inflammation, which can occur independently of steatosis), fibrosis (excessive deposition of extracellular matrix), and cirrhosis. These stages typically display an increasing pathological gradient (scarring). The latter is a late-stage liver disorder that might develop into potentially fatal side effects such hepatocellular cancer, portal hypertension, or liver collapse. [3].

The gold standard for assessing hepatic pathology is still liver biopsy, which is a key component of treatment plans for hepatitis B patients. Hepatitis B has a heterogeneous pathology that reflects the course of the illness naturally. Acute infections, acute flare-ups of illness, and acute hepatitis D superinfection all exhibit an acute hepatitic pattern with lobular disruption. Inflammation in chronic hepatitis B is more pronounced during immune-mediated viral clearance and less pronounced during the immune-tolerant phase. Fibrosis formation appears to be fueled by active inflammation. As with hepatitis C, inflammatory grades and fibrosis stages are ascribed.

Throughout the world, chronic hepatitis B virus (HBV) infection is a leading factor in liver morbidity and mortality. While some of the 250 million people with chronic HBV infection won't experience serious consequences or need treatment, many others run the danger of developing end-stage liver disease problems such decompensated cirrhosis and hepatocellular carcinoma (HCC) without treatment. Patients need a professional evaluation due to the complicated natural course of HBV infection in order to interpret biochemistry, viral serology, and accurately stage the disease, as well as to start monitoring and/or therapy when necessary. For the management of the disease and the prognosis of an individual with HBV, the detection and quantification of liver fibrosis is crucial.

Hepatitis B has a complex pathophysiology that corresponds to the disease's clinical history. Most patients recover from acute infection, but some go on to become chronic hepatitis B. Immune-tolerant, immune-reactive, and inactive hepatitis B virus (HBV) carrier stages make up the course of chronic hepatitis B. The traditional gold standard for determining the extent of liver injury, including both inflammatory activity and stage of fibrosis, is liver biopsy. Additionally, a liver biopsy can help to detect and assess complicating disorders such steatohepatitis, autoimmune hepatitis, and drug-induced liver disease as well as precursor lesions of hepatocellular carcinoma (HCC). However, current hepatitis B care recommendations do not mandate liver biopsy in all patients with chronic hepatitis B; rather, they base this recommendation on a patient's overall health [4,5].

Conclusion

With 1.3 million deaths reported in 2017, CLD is responsible for more than 2 million deaths each year. The pathological progression of CLD, however, can be stopped, slowed down, and in some cases reversed with early disease diagnosis and appropriate disease management that monitors disease progression in response to treatments, thereby lowering the risk of decompensated cirrhosis, HCC, and/or liver failure. Appropriate diagnostic and prognostic measures are crucial because they can improve patient outcomes and reduce morbidity and mortality linked to CLD.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Granata, Vincenza, Roberta Grassi, Roberta Fusco and Andrea Belli, et al. "Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma." Infect Agents Cancer 16 (2021): 1-22.

Google Scholar, Crossref, Indexed at

2. Garrido, Amanda and Nabil Djouder. "Cirrhosis: a questioned risk factor for hepatocellular carcinoma." Trends Cancer 7 (2021): 29-36.

Google Scholar, Crossref, Indexed at

3. Fan, Sheung Tat, Chung Mau Lo, Ronnie TP Poon and Chun Yeung, et al. "Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: A 20-year experience." Ann Surg 253 (2011): 745-758.

Google Scholar, Crossref, Indexed at

4. Poon, Ronnie TP, Sheung Tat Fan, Chung Mau Lo and Chi Leung Liu, et al. "Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: Impact on long-term survival." Ann Surg 245 (2007): 51.

Google Scholar, Crossref, Indexed at

5. Infante‐Rivard, Claire, Santiago Esnaola and Jean‐Pierre Villeneuve. "Clinical and statistical validity of conventional prognostic factors in predicting short‐term survival among cirrhotics." J Hepatol 7 (1987): 660-664.

Google Scholar, Crossref, Indexed at